Work

Can post-neoadjuvant therapy molecular classification guide future treatment selection for muscle-invasive bladder cancer?

Year: 2019

Type: article

Abstract: chemotherapy enhances immune responses (9-12).How these observations affect clinical practice remains to be seen.To contribute to management decisions in the clinic, data regarding the post-treatment consensus clusters and subsequent therapy response is needed.To be fully integrated into clinical management decisions, there is the need to develop single sample subtype classifiers, as the authors did with treatment-naïve tissue.These classifiers will be adopted only after validation from trials evaluating treatment response prospectively guided by subtype classification.Moreover, with the recent report of significant responses to neoadjuvant immunotherapy (13), there is great opportunity to develop better multitargeted combination strategies to maximize benefits for muscle invasive bladder cancer patients.

Source: Translational Andrology and Urology

DOI: 10.21037/tau.2018.12.07

Authors: David J. VanderWeele, Joshua J. Meeks, Maha Hussain

Institutions: Northwestern University, Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funders: Prostate Cancer Foundation, Hope Foundation, National Institutes of Health